5 completed, 3 terminated. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Terminated 3 |
| Phase 1 | 1 | Terminated 1 |
Follow Myeloproliferative Diseases: new trials by email Literature Review of Myeloproliferative Diseases trials Research Report on Myeloproliferative Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) Pacritinib, Busulfan, Questionnaires - Myeloproliferative Diseases | Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2015-06-15 | 2018-10-30 |
| Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF) Ruxolitinib, Pracinostat, Questionnaire - Myeloproliferative Diseases | Phase 2 | Completed | M.D. Anderson Cancer Center | 25 | 2015-01-12 | 2019-06-12 |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene Fludarabine, Melphalan, Alemtuzumab - Leukemia, Myeloma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2013-12-27 | 2019-07-16 |
| Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning Fludarabine monophosphate, Busulfan, Stem Cell Infusion - Leukemia, Acute Myeloid Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 201 | 2012-04-11 | 2023-06-29 |
| Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) Fludarabine, Melphalan, Alemtuzumab - Leukemia, Lymphoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 16 | 2012-02-01 | 2016-03-17 |
| Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) Clofarabine, Cytarabine - Leukemia, Myeloproliferative Diseases | Phase 2 | Completed | M.D. Anderson Cancer Center | 81 | 2011-11-16 | 2018-07-03 |
| Ruxolitinib and Lenalidomide for Patients With Myelofibrosis Ruxolitinib, Lenalidomide, Prednisone - Myeloproliferative Diseases | Phase 2 | Completed | M.D. Anderson Cancer Center | 31 | 2011-09-22 | 2025-06-08 |
| Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases ITF2357 - Myeloproliferative Diseases | Phase 2 | Completed | Italfarmaco | 29 | 2007-12-01 | 2019-12-03 |
Leukemia (4) · Myelodysplastic Syndromes (4) · Polycythemia Vera (4) · Primary Myelofibrosis (4) · Hodgkin Disease (3) · Multiple Myeloma (3) · Lymphoma (2) · Neoplasms, Plasma Cell (2) · Thrombocythemia, Essential (2) · Graft vs Host Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Myeloproliferative Disorders (1)
Bone Marrow Diseases (8) · Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Neoplasms (8) · Hemorrhagic Disorders (5) · Bone Marrow Neoplasms (4) · Hematologic Neoplasms (4) · Myeloproliferative Disorders (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Blood Protein Disorders (3) · Cardiovascular Diseases (3) · Hemostatic Disorders (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3)
fludarabine phosphate (4) · Filgrastim (3) · Granulocyte Colony-Stimulating Factor (3) · Surveys and Questionnaires (3) · Tacrolimus (3) · fludarabine (3) · Alemtuzumab (2) · Busulfan (2) · Melphalan (2) · Methotrexate (2) · ruxolitinib (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · AP 1903 reagent (1) · Clofarabine (1) · Cytarabine (1)
M.D. Anderson Cancer Center (7) · Italfarmaco (1)
United States (7) · Italy (1)
Srdan Verstovsek, MD (2) · Uday Popat, MD (2) · Alessandro Rambaldi, MD (1) · Guillermo Garcia-Manero, MD (1) · Richard E. Champlin, MD, BS (1) · Richard E. Champlin, MD,BS (1)